We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
NLS Pharmaceutics Ltd

NLS Pharmaceutics Ltd (NLSP)

Closed June 19 4:00PM
After Hours: 7:59PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.2304 Day's Range 0.4597
0.1112 52 Week Range 1.53
Previous Close
Last Trade Time
Average Volume (3m)
Financial Volume
$ 97,319,645

NLSP Latest News

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
CMTLComtech Telecommunications Corporation
$ 4.07
NLSPNLS Pharmaceutics Ltd
$ 0.2735
ASNSActelis Networks Inc
$ 2.11
RELIReliance Global Group Inc
$ 0.40
LRHCLa Rosa Holdings Corporation
$ 1.78
STISolidion Technology Inc
$ 0.6881
DMTKDermTech Inc
$ 0.1488
QMCOQuantum Corporation
$ 0.3752
ZNTLZentalis Pharmaceuticals Inc
$ 4.135
AWINAERWINS Technologies Inc
$ 1.74
RELIReliance Global Group Inc
$ 0.40
NLSPNLS Pharmaceutics Ltd
$ 0.2735
NVDANVIDIA Corporation
$ 135.58
MBIOMustang Bio Inc
$ 0.8517
CRKNCrown Electrokinetics Corporation
$ 0.0548

NLSP Discussion

View Posts
trader59 trader59 18 hours ago
Computer generated wash trading. The O/S of about 40M has already been tossed over 6X's today, brazen manipulation. Don't get trapped.
CarlCarlMcB CarlCarlMcB 23 hours ago
Harpoon $$$$$ white water $$$$ full run ahead $$$$$$$
glenn1919 glenn1919 2 days ago
adamski adamski 1 week ago
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
The Night Stalker The Night Stalker 3 weeks ago
reminds me of SXTP volume build up then breakout volume, man we see 10m volume hit there we pop big
The Night Stalker The Night Stalker 3 weeks ago
volume alert
Monksdream Monksdream 1 month ago
NLSP under 25 cents
glenn1919 glenn1919 1 month ago
Invest-in-America Invest-in-America 3 months ago
NLSP: Grabbed it!! Let's kick-ASK!!!
Invest-in-America Invest-in-America 3 months ago
NLSP: And with a Big Pharma (US) Firm, to boot --- no 'small potatoes' routine here.
adamski adamski 3 months ago
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

The exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target multiple pathways in neuropharmacological therapies.
Medications activating dual OX1R/OX2R target a broader range of mechanisms involved in neurologic disorders including narcolepsy and other hypersomnolence disorders
Additional targets covered by the exclusive License Agreement include cathepsins, sigma receptors and catecholaminergic inhibition, addressing neuroprotection, neuroinflammation and neurotransmission.
First patent application was filed at the end of 2022 for orexin receptors agonists for treating or preventing neurological diseases and psychiatric disorders including narcolepsy.
With this groundbreaking License Agreement, NLS continues to strengthen its neuroscience pipeline in sleep medicine with a unique and holistic approach to central disorders of hypersomnolence and neurodegenerative disorders franchise.
NLS to start immediately focusing on these disease modifying compounds which have the potential to be first as well as best in class.
81vette 81vette 7 months ago
Moving up on very little vol now,like it should all natural,nice higher highs and lows since noon,vwap is .59 for resistance,support.49/.50
81vette 81vette 7 months ago
Mehโ€ฆnot skerdโ€ฆloaded 30k under .50,late Nov last year ran from .50 to 1.75 on only patient approved,todayโ€™s vol had to be institutional starting to add,no way this was all retail with all the other good plays today,risk is low unless they do offering but none since inception,mmx (mm)shorted this down today(currently the 88k on ask) once gone should head up again is my play.mkts all a gamble,dice rolling now
81vette 81vette 7 months ago
Bounce expected off sma200(1min) .50(mental support also)
81vette 81vette 7 months ago
Float rotation 1X in first hr trading,mid day vol surge expected between 11:30-1,if before that confidence strong and should continue up all day
81vette 81vette 7 months ago
Cash 9M,no debt,gaining watchers fast,itโ€™s death hour and itโ€™s still higher highs and lows,vwap(1min) is .604 bounced itโ€™s head off that resistance,watching for thru .61 to continue well
81vette 81vette 7 months ago
Institutions own 29%,should be adding with this potential of profits ,insiders own 38%
81vette 81vette 7 months ago
News was only on accesswire,not showing on 3 of my platforms yet.,any min. Should be on ap and other pumpers news with this vol
81vette 81vette 7 months ago
Heading to ZERO BORROW,only 95k remain
81vette 81vette 7 months ago
50Xs ave vol.,1268Xs ave buying vol. insane volume!!
subslover subslover 7 months ago
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential treatment of narcolepsy and other neuro-degenerative disorders, and all future indications
Exclusive option agreement accesses global rights to multiple highly selective Orexin-1 / Orexin-2 receptor agonists, unique compounds designed for specificity, acting multiple pathways involved in the pathophysiology of narcolepsy and other central disorders of hypersomnolence
Additional targets include Cathepsin-H inhibition, sigma-1 receptor agonist, DAT and NET reuptake inhibition, addressing neurotransmission, neuroprotection and neuroinflammation
First patent application filed at the end of 2022 for orexin receptors agonists for treating or preventing neurological diseases and psychiatric disorders including narcolepsy
NLS continues to strengthen its neuroscience pipeline in sleep medicine with a unique and holistic approach to central disorders of hypersomnolence and neurodegenerative disorders franchise
ZรœRICH, SWITZERLAND / ACCESSWIRE / December 1, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system ("CNS") disorders, today announced that NLS has entered into an exclusive worldwide option agreement with Aexon Labs, Inc., a privately held U.S. company ("Aexon Labs"), under which NLS may acquire global development and commercialization rights to Aexon Labs' Dual Orexin Receptor Agonists platform, new molecular entities, highly selective dual oral orexin-1 and orexin-2 receptor agonists (OX1R and OX2R) with potential applications in the treatment of narcolepsy and idiopathic hypersomnia, as well as neuro-degenerative disorders such as Parkinson's and Alzheimer's disease. This option agreement represents a potentially leading next-generation, first-in-class, oral, dual orexin receptor agonist (AEX-2) that is expected to address high unmet medical needs and has shown promising results in pre-clinical in vitro assays. Aexon Labs has plans to initiate clinical development, including Phase 1 First-in-Human and Phase 1b Proof-of-Concept (POC) studies, as early as 2024.

The transaction will be structured as an exclusive worldwide license for the development and commercialization by NLS of the Aexon Labs' compounds and their derivatives. Under the terms of the option agreement, NLS must exercise its option by no later than March 31, 2024. NLS will pay Aexon Labs an upfront payment of $30,000 for the option exclusivity, and $170,000 upon execution of the definitive agreement to exercise the option. In addition, Aexon Labs will receive 15% of all proceeds earned by NLS in any future sub-licensing agreements which include upfront payments, regulatory milestones, commercial milestones and royalties earned during the first three years of commercialization in the U.S. and in the EU. Royalties will be payable, on a country-by-country basis, from the date of first commercial sale of a product in a given country until the date of patent expiry or the entry of a generic version of the product in such country.

NLS will be the sole party responsible for the design and execution of the research and development plan, for the conduct and management of the preclinical as well as clinical studies, and for the interactions with the U.S. Food and Drug Administration and/or any other regulatory agency. NLS will pay all costs associated with executing and completing those studies, as well as those associated with the preparation and submission of a new drug application. NLS will pay for all studies in all indications and regulatory filings in the U.S. as well as outside of the U.S.

Eric Konofal, MD, PhD, who works under a part-time consulting agreement for NLS as its Chief Scientific Officer, is the president and founder of Aexon Labs, and owns 59% of Aexon Labs. Alexander Zwyer, Chief Executive Officer of NLS, owns 35% of Aexon Labs. Mr. Zwyer holds no board or executive position at Aexon Labs.

Mr. Zwyer said, "I believe the potential acquisition of this novel and unique platform which consists of over 300 compounds, bridges the present to the future treatment of sleep disorders as well as other neuro-degenerative disorders. These new compounds, in addition to our current pipeline, including Mazindol ER for the treatment of narcolepsy, along with NLS-4 focused on idiopathic hypersomnia, long-COVID and chronic fatigue syndrome, and NLS-11, addressing Kleine-Levin Syndrome and neurodegenerative diseases will further complement and strengthen our hypersomnia franchise."

Orexin receptor pathways play vital regulatory roles in many physiological processes and studies have shown that orexin receptor pathways are involved in pathological processes of neurological diseases such as narcolepsy, depression, ischemic stroke, drug addiction and Alzheimer's disease.

About Narcolepsy

Narcolepsy is a life-long sleep disorder caused by the autoimmune-mediated loss of 70,000-90,000 orexin-producing neurons in the hypothalamus, characterized by excessive daytime sleepiness, cataplexy and rapid eye movement sleep abnormalities, and is tightly associated with human leukocyte antigen HLA-DQB1*06:02. Other predisposing factors for narcolepsy are associations with a polymorphism in the T-cell receptor alpha and beta genes, whose products recognize antigens presented by human leukocyte antigens (HLA) molecules, and Cathepsin H (CTSH).

About NLS Pharmaceutics Ltd.

NLS is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit

About Aexon Labs, Inc.

Aexon Labs is conducting leading edge research on new compounds to address unmet needs in neurodegenerative disorders, defined by the breakdown of neurons over time. Alzheimer's, Parkinson's, Huntington's, Narcolepsy and Amyotrophic Lateral Sclerosis are just a few examples of brain disorders that have no cure. Current treatments do not address the root cause of each disorder and often lack therapeutical effectiveness and safety for these neurological disorders. For more information, please visit

Safe Harbor Statement

This press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses the potential benefits of NLS' and Aexon Labs' products, development plans and timing of studies, and the timing and the expected outcome of the option agreement. These forward-looking statements and their implications are based on the current expectations of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its clinical trials; NLS' products may not be approved by regulatory agencies, NLS' technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS' process; NLS' products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS' patents may not be sufficient; NLS' products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS' annual report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC), which is available on the SEC's website,, and in subsequent filings made by NLS with the SEC.

For additional information:

Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500

SOURCE: NLS Pharmaceutics AG

View source version on
Michael TRed Michael TRed 7 months ago
Smell money tomorrow ; )
reena969 reena969 10 months ago
Slowly adding...........while others focus on the meme stocks.
NYCJR NYCJR 1 year ago
big time runner in the making here, added a ton in the low 40s a few months back!
Laster Laster 1 year ago
Great looking chart.
Breakout over $1.10.
Just needs some volume.
microchips microchips 2 years ago
About time for this one to move up. First PT at .60
willlbone willlbone 2 years ago
Wake up. Time to sell.
trendzone trendzone 2 years ago
Starting to bounce after the pull back from the big run up the other day.
pauljack13 pauljack13 2 years ago
No posts yet. Iโ€™ll start. I bought this last year after the IPO in the 3โ€™s and sold it after a 1 day spike to 7.

Looks like itโ€™s about to do another 1 day double. Low floater here.